Turnhout, Belgium

Jean-Pierre André Marc Bongartz

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 7.9

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2007-2017

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Jean-Pierre André Marc Bongartz

Introduction

Jean-Pierre André Marc Bongartz is a notable inventor based in Turnhout, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as protein tyrosine kinase inhibitors. With a total of seven patents to his name, Bongartz has established himself as a key figure in innovative drug development.

Latest Patents

Bongartz's latest patents include a process for the preparation of heterocyclic ester derivatives. This invention focuses on creating compounds that are useful as intermediates in synthesizing derivatives that inhibit c-fms kinase. Another significant patent involves piperidine/piperazine derivatives, which relate to a DGAT inhibitor. This invention encompasses various stereochemically isomeric forms and outlines methods for preparing these compounds, which have potential applications in medicine.

Career Highlights

Bongartz is currently associated with Janssen Pharmaceutica NV, a leading company in the pharmaceutical industry. His work has contributed to advancements in drug formulations and therapeutic applications, showcasing his expertise in the field.

Collaborations

Throughout his career, Bongartz has collaborated with esteemed colleagues such as Guy Rosalia Eugeen Van Lommen and Erwin Coesemans. These partnerships have further enhanced his research and development efforts, leading to innovative solutions in pharmaceuticals.

Conclusion

Jean-Pierre André Marc Bongartz's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the development of important medical compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…